Cargando…
Identification of SYK inhibitor, R406 as a novel senolytic agent
The selective removal of senescent cells by senolytics is suggested as a potential approach to reverse aging and extend lifespan. Using high-throughput screening with replicative senescence of human diploid fibroblasts (HDFs), we identified a novel senolytic drug R406 that showed selective toxicity...
Autores principales: | Cho, Hyun-Ji, Yang, Eun Jae, Park, Joon Tae, Kim, Jae-Ryong, Kim, Eok-Cheon, Jung, Kyong-Jin, Park, Sang Chul, Lee, Young-Sam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244031/ https://www.ncbi.nlm.nih.gov/pubmed/32379705 http://dx.doi.org/10.18632/aging.103135 |
Ejemplares similares
-
Nintedanib induces senolytic effect via STAT3 inhibition
por: Cho, Hyun-Ji, et al.
Publicado: (2022) -
The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance
por: Duran, George E., et al.
Publicado: (2019) -
Senotherapeutics: emerging strategy for healthy aging and age-related disease
por: Kim, Eok-Cheon, et al.
Publicado: (2019) -
Dehydroabietic Acid Suppresses Inflammatory Response Via Suppression of Src-, Syk-, and TAK1-Mediated Pathways
por: Kim, Eunji, et al.
Publicado: (2019) -
R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells
por: Sun, Shuxin, et al.
Publicado: (2019)